Biological Polymerase Chain Reaction (PCR) Technology Market Report 2025

The biological polymerase chain reaction (PCR) technology market size has grown rapidly in recent years. It will grow from $15.06 billion in 2024 to $16.62 billion in 2025 at a compound annual growth rate (CAGR) of10.3%. The growth in the historic period can be attributed to the expansion of forensic DNA analysis, increased funding for academic and clinical research, advancements in agricultural biotechnology, the growth of the biopharmaceutical industry, and the rise of genetic testing services.

The biological polymerase chain reaction (PCR) technology market size is expected to see rapid growth in the next few years. It will grow to $24.31 billion in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to advancements in miniaturization and point-of-care (PoC) devices, the increasing adoption of liquid biopsy and non-invasive testing, supportive regulatory frameworks with expedited approvals, higher consumption of reagents and consumables, and strong funding from both government and private sectors. Key trends expected during this period include the development of microfluidic PCR systems, enhancements in real-time PCR, advancements in multiplex PCR technology, integration with next-generation sequencing, and the application of AI and machine learning for PCR data analysis.

The rising incidence of infectious diseases is expected to drive the growth of the biological polymerase chain reaction (PCR) technology market in the coming years. Infectious diseases are illnesses caused by bacteria, viruses, fungi, or parasites, and their prevalence is increasing due to global travel, which accelerates the spread of pathogens across regions. Biological PCR technology plays a crucial role in combating infectious diseases by enabling rapid and accurate pathogen detection, supporting early diagnosis, timely treatment, and effective outbreak management. For example, in November 2023, the World Health Organization, a Switzerland-based intergovernmental body, reported that there were an estimated 249 million malaria cases worldwide in 2022, reflecting an increase of 5 million cases (2%) compared to 2021. As a result, the rising burden of infectious diseases is fueling demand for biological PCR technology.

Companies in the biological PCR technology market are innovating with advanced approaches such as microfluidic partitioning to improve sensitivity, accuracy, and throughput in PCR-based diagnostics and research. Microfluidic partitioning involves dividing a liquid sample into thousands or millions of tiny, uniform compartments (droplets or wells) using microfluidic systems. For example, in August 2022, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, launched its digital PCR (dPCR) system, a next-generation diagnostic platform for cancer and other diseases. This system leverages microfluidic partitioning to split a sample into numerous reaction compartments, enabling absolute quantification of DNA or RNA without the need for standard curves. With exceptional sensitivity and precision, dPCR is particularly effective for detecting rare mutations, minimal residual disease, and low-abundance targets.

In July 2025, Bio-Rad Laboratories Inc., a US-based life science research and clinical diagnostics company, acquired Stilla Technologies SA for an undisclosed amount. This acquisition strengthens Bio-Rad’s position in the digital PCR market and expands its molecular diagnostics capabilities by incorporating Stilla’s advanced crystal digital PCR technology. Stilla Technologies SA is a France-based provider specializing in biological PCR technology.

Major players in the biological polymerase chain reaction (PCR) technology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Agilent Technologies Inc., Sartorius AG, Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Eppendorf AG, Cepheid Inc., Bio-Techne Corporation, GenScript Biotech Corporation, Takara Bio Inc., Promega Corporation, Analytik Jena GmbH+Co. KG, New England Biolabs Inc., Enzo Biochem Inc., LGC Biosearch Technologies Inc., and Bioline Reagents Ltd.

North America was the largest region in the biological polymerase chain reaction (PCR) technology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biological polymerase chain reaction (PCR) technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biological polymerase chain reaction (PCR) technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Biological polymerase chain reaction (PCR) technology is a laboratory technique used to generate multiple copies of a specific DNA segment from a very small initial sample. The process involves repeated temperature cycles that separate DNA strands, allow primers to attach, and enable enzymes to build new DNA strands. Through this cyclical reaction, PCR rapidly amplifies the target DNA with high precision and accuracy, making it a critical tool for genetic research and analysis.

The primary product types of biological PCR technology include reagents, consumables, and software and services. Reagents are chemical substances used in PCR reactions to detect, amplify, or quantify DNA or RNA. The technology encompasses multiple techniques such as real-time PCR, conventional PCR, digital PCR, reverse transcription PCR, hot-start PCR, multiplex PCR, and others. Its applications span diagnostic testing, genotyping, nucleic acid detection, gene expression analysis, nucleic acid synthesis, genetic sequencing, environmental studies, standard validation or verification, and more. End users include hospital laboratories, diagnostic laboratories, academic and government research organizations, pharmaceutical and biotechnology companies, among others.

The biological polymerase chain reaction (PCR) technology market research report is one of a series of new reports that provides biological polymerase chain reaction (PCR) technology market statistics, including biological polymerase chain reaction (PCR) technology industry global market size, regional shares, competitors with a biological polymerase chain reaction (PCR) technology market share, biological polymerase chain reaction (PCR) technology market segments, market trends and opportunities, and any further data you may need to thrive in the biological polymerase chain reaction (PCR) technology industry. This biological polymerase chain reaction (PCR) technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biological polymerase chain reaction (PCR) technology market consists of revenues earned by entities by providing services such as DNA amplification, genetic testing, and pathogen detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The biological polymerase chain reaction (PCR) technology market also includes sales of enzymes, primers, probes, and thermal cyclers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.